TISIDB

Summary
Symbol	CEBPD
Name	CCAAT/enhancer binding protein (C/EBP), delta
Aliases	CELF; C/EBP-delta; NF-IL6-beta; c/EBP delta; nuclear factor NF-IL6-beta; CCAAT/enhancer-binding protein delt ......
Chromosomal Location	8p11.2-p11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF07716 Basic region leucine zipper
Function	Transcription activator that recognizes two different DNA motifs: the CCAAT homology common to many promoters and the enhanced core homology common to many enhancers (PubMed:16397300). Important transcription factor regulating the expression of genes involved in immune and inflammatory responses (PubMed:1741402, PubMed:16397300). Transcriptional activator that enhances IL6 transcription alone and as heterodimer with CEBPB (PubMed:1741402).

> Gene Ontology [ TOP ]
Biological Process	GO:0001503 ossification GO:0001649 osteoblast differentiation GO:0002244 hematopoietic progenitor cell differentiation GO:0007423 sensory organ development GO:0030278 regulation of ossification GO:0043583 ear development GO:0045444 fat cell differentiation GO:0045667 regulation of osteoblast differentiation GO:0045669 positive regulation of osteoblast differentiation GO:0045778 positive regulation of ossification GO:0048839 inner ear development
Molecular Function	GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0000987 core promoter proximal region sequence-specific DNA binding GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001159 core promoter proximal region DNA binding GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0046982 protein heterodimerization activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-1266738: Developmental Biology R-HSA-168256: Immune System R-HSA-6785807: Interleukin-4 and 13 signaling R-HSA-449147: Signaling by Interleukins R-HSA-381340: Transcriptional regulation of white adipocyte differentiation

Summary
Symbol	CEBPD
Name	CCAAT/enhancer binding protein (C/EBP), delta
Aliases	CELF; C/EBP-delta; NF-IL6-beta; c/EBP delta; nuclear factor NF-IL6-beta; CCAAT/enhancer-binding protein delt ......
Chromosomal Location	8p11.2-p11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CEBPD and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between CEBPD and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
23861541	Nasopharyngeal Carcinoma	Inhibit immunity	We showed that immunosuppressive prostaglandin E? (PGE?) led to the production and activity of the transcription factor CCAAT/enhancer binding protein δ (C/EBPδ) by stimulating the nucleocytoplasmic shuttling of the RNA binding protein Hu antigen R (HuR), which bound to and stabilized CEBPD mRNA in macrophages. An increase in C/EBPδ abundance in macrophages in response to PGE? resulted in enhanced production of the immunosuppressive cytokine interleukin-10 (IL-10) and of pentraxin 3 (PTX3), which suppresses the ability of macrophages to phagocytose tumor cells.

Summary
Symbol	CEBPD
Name	CCAAT/enhancer binding protein (C/EBP), delta
Aliases	CELF; C/EBP-delta; NF-IL6-beta; c/EBP delta; nuclear factor NF-IL6-beta; CCAAT/enhancer-binding protein delt ......
Chromosomal Location	8p11.2-p11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CEBPD in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CEBPD
Name	CCAAT/enhancer binding protein (C/EBP), delta
Aliases	CELF; C/EBP-delta; NF-IL6-beta; c/EBP delta; nuclear factor NF-IL6-beta; CCAAT/enhancer-binding protein delt ......
Chromosomal Location	8p11.2-p11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CEBPD in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.363	0.481
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.081	0.67
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.153	0.939
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.088	0.88
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.426	0.86
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.34	0.913
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.303	0.457
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.259	0.81
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.441	0.732
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.354	0.766
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.039	0.983
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.418	0.0011

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CEBPD in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	0	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	0	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CEBPD
Name	CCAAT/enhancer binding protein (C/EBP), delta
Aliases	CELF; C/EBP-delta; NF-IL6-beta; c/EBP delta; nuclear factor NF-IL6-beta; CCAAT/enhancer-binding protein delt ......
Chromosomal Location	8p11.2-p11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CEBPD. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CEBPD
Name	CCAAT/enhancer binding protein (C/EBP), delta
Aliases	CELF; C/EBP-delta; NF-IL6-beta; c/EBP delta; nuclear factor NF-IL6-beta; CCAAT/enhancer-binding protein delt ......
Chromosomal Location	8p11.2-p11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CEBPD. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CEBPD. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CEBPD
Name	CCAAT/enhancer binding protein (C/EBP), delta
Aliases	CELF; C/EBP-delta; NF-IL6-beta; c/EBP delta; nuclear factor NF-IL6-beta; CCAAT/enhancer-binding protein delt ......
Chromosomal Location	8p11.2-p11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CEBPD. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CEBPD
Name	CCAAT/enhancer binding protein (C/EBP), delta
Aliases	CELF; C/EBP-delta; NF-IL6-beta; c/EBP delta; nuclear factor NF-IL6-beta; CCAAT/enhancer-binding protein delt ......
Chromosomal Location	8p11.2-p11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CEBPD expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CEBPD
Name	CCAAT/enhancer binding protein (C/EBP), delta
Aliases	CELF; C/EBP-delta; NF-IL6-beta; c/EBP delta; nuclear factor NF-IL6-beta; CCAAT/enhancer-binding protein delt ......
Chromosomal Location	8p11.2-p11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CEBPD and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CEBPD
Name	CCAAT/enhancer binding protein (C/EBP), delta
Aliases	CELF; C/EBP-delta; NF-IL6-beta; c/EBP delta; nuclear factor NF-IL6-beta; CCAAT/enhancer-binding protein delt ......
Chromosomal Location	8p11.2-p11.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CEBPD collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CEBPD